Chemistree Technology, Inc. – Special Report
Chemistree Technology Inc. is self-billed as an investment company which provides turn-key solutions for the regulated cannabis industry through the development of vertically integrated cannabis assets, including licensed cultivation, processing, distribution and retail facilities.
Perhaps the most impressive aspect of CHMJF is the rapidity with which the company has gone about executing its corporate strategy. In just the past year, it has acquired and/or developed cannabis assets in California and Washington State, with even more currently under construction.
In Washington State last May, the company acquired the Sugarleaf cannabis brand, along with the growing and processing facility that produces it, and all associated licenses. Sugarleaf branded cannabis is currently available in more than twenty retail locations, with plans to expand that to more than a hundred outlets in the next year. The company expects to generate roughly $2.7M in 2019 revenue for this facility alone.
In California, Chemistree has arranged a strategic collaboration with a Humboldt county cannabis-to-CBD processing company. CHMJF provided a $450K loan in exchange for immediate access to the California markets and the ability to purchase cannabis for processing at the facility, which it expects to bring in as much as $1.5M in revenue in 2019 alone.
Additionally, the company purchased 9.55 acres of land in cannabis-hotspot, Desert Hot Springs, California last year. It has completed the continuous-use permit, and is currently finalizing plans for two 64,000 square foot greenhouses and a 40,000 square foot manufacturing and distribution facility, subject to the approval of the city planner’s office.
These highlights only scratch the surface of what CHMJF has accomplished in just the last year, and hint at a promising finish to 2019, along with a bright future beyond. CHMJF has quickly become an area of special interest for us in the cannabis space.
IMPORTANT! All readers should take the time to
>>VIEW this IN-DEPTH OVERVIEW of CHMJF<<
MOST RECENT DEVELOPMENT: VANCOUVER, April 29, 2019 /PRNewswire/ – Chemistree Technology Inc. (CSE: CHM and CHM.wt) (US OTCQB: CHMJF) (the “Company” or “Chemistree”), is pleased to announce that the Company has entered into a funding agreement with The Physician’s Choice CBD LLC of Phoenix, Arizona.
The Physician’s Choice CBD (“PCCBD”) is dedicated to research, development, and utilization of the highest quality of hemp-derived cannabidiol (CBD) combined with well-studied and effective supplements specific to help regulate and support various symptoms. The integration of extensive physician clinical experience combined with exhaustive expertise in the cannabis industry has led to the creation of The Physician’s Choice CBD. (>>View Full PR)
For More Information on CHMJF, visit:
Don’t forget to check out THIS REPORT on CHMJF!
Incoming search terms: